NCT05607537View on ClinicalTrials.gov

A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

E7386 Tablet

E7386 40 mg tablet.

DRUG

(14C)E7386 Capsule

(14C)E7386 40 mg capsule.

DRUG

(14C)E7386

(14C)E7386 administered intravenously.

Trial Locations (1)

LS11 9EH

Labcorp Clinical Research Unit, Leeds

All Listed Sponsors
lead

Eisai Limited

INDUSTRY